Novel polypeptides, materials and methods for making them, and method of use are disclosed. The polypeptides comprise residues 41-150 of SEQ ID NO:2 or residues 32-141 of SEQ ID NO:4, and may be prepared as polypeptide fusions comprise heterologous sequences, such as affinity tags. The polypeptides and polynucleotides encoding them may be used within a variety of therepeutic, diagnostic, and research applications.

EXAMPLES 
 Example 1 A PCR panel comprising 94 cDNA samples plus human genomic DNA and water controls was screened for the presence of zcub5 sequences. PCR reactions were set up using oligonucleotide primers ZC28,499 (SEQ ID NO:18) and ZC28,500 (SEQ ID NO:19), a DNA polymerase (Ex Taq™; Takara Shozu, Japan) plus antibody mixture, an annealing temperature of 63.0° C., and an extension time of 30 seconds for a total of 35 cycles. Results are shown in Table 4. 4 TABLE 4 Re- Re- Source* sult Source sult Adrenal Gland − Bladder − Bone Marrow − Brain − Cervix &plus; Colon &plus; Fetal Brain − Fetal Heart &plus;/− Fetal Kidney − Fetal Liver &plus; Fetal Lung − Fetal muscle − Fetal Skin − Heart − Heart − K562 (human chronic − myelogenous leukemia) Kidney − Liver − Lung − Lymph Node − Melanoma − Pancreas − Pituitary &plus;/− Placenta &plus; Prostate − Rectum &plus; Salivary Gland − Skeletal Muscle − Small Intestine &plus; Spinal Cord − Spleen &plus; Stomach &plus;/− Testis − Testis − Thymus − Thyroid − Trachea − Uterus − bone marrow library − fetal brain library &plus; islet library − prostate 0.5-1.6 kb library − prostate >1.6 kb library &plus; prostate smc library − RPMI 1788 (B−cell) library &plus; testis library &plus; thyroid Library &plus; WI38 (lung fibroblast) &plus; library WI−38 (lung fibroblast) &plus; RPMI 1788 (B-cell) library &plus; library Thyroid library &plus; Islet library &plus; HPV (prostate epithelia) &plus; HaCAT (keratinocyte) library &plus; library Bone Marrow library − Adrenal Gland library &plus; Prostate smc library &plus; Prostate library − Fetal Brain library &plus; Testis library &plus; HPVS (prostate epithelia) &plus; CD3&plus; (2) library − library Fetal Brain arr. library &plus; Bone Marrow arr. library &plus; Pituitary arr. library − Heart arr. library − Salivary Gland arr. library − Placenta arr. library − Testis 10 K pools arr. &plus; Testis 1 K pools arr. library &plus; library Gastric CA − Esophagus CA &plus; Liver CA − Kidney CA &plus; Ovarian CA &plus; Lung CA &plus; Uterus CA − Rectal CA &plus; Platelet library − HL60 (promyelocytic − leukemia) HL60 &lgr;gt11 library − HBL−100 (breast epithelial) − library Renal mesangial library &plus;/− HL60 &num;2 &lgr;gt11 − &num;2 &lgr;gt11 Neutrophil &lgr;gt11 library − T-cell &lgr;gt11 library − 3.83 × 10 7 pfu Fibroblast &lgr;gt11 library &plus; Entamoeba histolytica &lgr;gt11 − Endothelial &lgr;gt11 library − HepG2 (hepatoma) &lgr;gt11 − HUT-102 (T-cell − gt 11 placenta cDNA library − lymphoma) cDNA lysate 5.17 × 10 7 pfu/&mgr;L Genomic DNA n.d. MPC &lgr;gt11 − Water − *Abbreviations used: CA, cancer; SMC, smooth muscle cell; arr., arrayed. 
 Example 2 PCR products (˜217 bp fragments) from the HPVS, testis, and ovarian cancer samples (Example 1) were sequenced. The HPVS fragment was confirmed to be a human zcub5 sequence. DNA fragments comprising zcub5 sequences were also obtained from various public and private sources and sequenced. A full-length zcub5 DNA was constructed by digestion and ligation of three clones from various sources. A consensus human zcub5 sequence is shown in SEQ ID NO:1, and the encoded amino acid sequence is shown in SEQ ID NO:2. 
 Example 3 A mouse cDNA panel was screened for zcub5 by PCR using oligonucleotide primers ZC 28,497 (SEQ ID NO:16) and ZC28,498 (SEQ ID NO:17), and a DNA polymerase (Ex Taq™; Takara Shozu, Japan) plus antibody mixture. The reaction was run for 35 cycles at an annealing temperature of 64. 1° C. with an extension time of 30 seconds. Positive results were obtained from brain, 15-day embryo library total pool, kidney, pancreas, salivary gland, spleen, stomach, testis, uterus, liver, lung, skeletal muscle, 7-day embryo, 11-day embryo, 15-day embryo, and 17-day embryo. Fragments (˜145 bp) from 15-day embryo library total pool, 15-day embryo, and kidney were sequenced and confirmed to be zcub5 sequence. The mouse 15-day embryo library was chosen for further screening. This library was an arrayed library representing 9.6×10 5 clones in the pCMV sport2 vector. A working plate containing 80 pools of 12,000 colonies each was screened by PCR for the presence of zcub5 DNA using oligonucleotide primers ZC28,497 (SEQ ID NO:16) and ZC28,498 (SEQ ID NO:17) with an annealing temperature of 64.1° C. for 35 cycles. One positive pool was plated and transferred to nylon filters (Hybond-NTM; Amersham Corporation, UK). The filters were denatured for 6 minutes in 0.5 M NaOH and 1.5 M Tris-HCl, pH 7.2, then neutralized in 1.5 M NaCl and 0.5 M Tris-HCl, pH 7.2 for 6 minutes. The DNA was affixed to the filters using a UV crosslinker (Stratalinker®; Stratagene, La Jolla, Calif.) at 1200 joules. The filters were prewashed at 65° C. in prewash buffer consisting of 0.25× SSC, 0.25% SDS, and 1 mM EDTA. The solution was changed a total of three times over a 45-minute period to remove cell debris. Filters were prehybridized overnight at 65° C. in 20 ml of a commercially available hybridization solution (ExpressHyb™ Hybridization Solution; Clontech Laboratories, Inc., Palo Alto, Calif.). A probe was generated by PCR using oligonucleotide primers ZC28,497 (SEQ ID NO:16) and ZC28,498 (SEQ ID NO:17), and an annealing temperature of 64.1° C. for 35 cycles and a mouse 15-day embryo cDNA library as template. The resulting PCR fragment was gel purified using a spin column containing a silica gel membrane (QIAquick™ Gel Extraction Kit; Qiagen, Inc., Valencia, Calif.). The probe was radioactively labeled with 32 p using a commercially available kit (Rediprime™ II random-prime labeling system; Amersham Corp., UK) according to the manufacturer's specifications and purified using a commercially available push column (NucTrap® column; Stratagene, La Jolla, Calif.). Hybridization took place overnight at 65° C. in commercially available hybridization solution. Filters were rinsed 6 times at 65° C. in pre-wash buffer, then exposed to film overnight at −80° C. Individual positive colonies were screened by PCR using oligonucleotide primers ZC28,497 (SEQ ID NO:16) and ZC28,498 (SEQ ID NO:17) and an annealing temp of 61.0° C. Two positive clones were sequenced and found to contain the same, full-length zcub5 sequence (SEQ ID NO:5), which was designated “muzcub5×3finalseq.” Two expressed sequence tags (EST) corresponding to portions of the zcub5 sequence were identified in a public database. Clones comprising these sequences were sequenced and found to encode an apparent splice variant of mouse zcub5 as shown in SEQ ID NO:3 (designated “muzcub5×2finalseq”). An alignment of human and mouse zcub5 amino acid sequences is shown in FIG. 2 . The gaps within the mouse sequences are believed to be due to alternative splicing. 
 Example 4 Recombinant zcub5 is produced in E. coli using a His 6 tag/maltose binding protein (MBP) double affinity fusion system as generally disclosed by Pryor and Leiting, Prot. Expr. Pur. 10:309-319, 1997. A thrombin cleavage site is placed at the junction between the affinity tag and zcub5 sequences. The fusion construct is assembled in the vector pTAP98, which comprises sequences for replication and selection in E. coli and yeast, the E. coli tac promoter, and a unique Smal site just downstream of the MBP-His 6 -thrombin site coding sequences. The zcub5 cDNA (SEQ ID NO:1) is amplified by PCR using primers each comprising 40 bp of sequence homologous to vector sequence and 25 bp of sequence that anneals to the cDNA. The reaction is run using Taq DNA polymerase (Boehringer Mannheim, Indianapolis, Ind.) for 30 cycles of 94° C., 30 seconds; 60° C., 60 seconds; and 72° C., 60 seconds. One microgram of the resulting fragment is mixed with 100 ng of Smal-cut pTAP98, and the mixture is transformed into yeast to assemble the vector by homologous recombination (Oldenburg et al., Nucl. Acids. Res. 25:451-452, 1997). Ura &plus; transformants are selected. Plasmid DNA is prepared from yeast transformants and transformed into E. coli MC1061. Pooled plasmid DNA is then prepared from the MC1061 transformants by the rniniprep method after scraping an entire plate. Plasmid DNA is analyzed by restriction digestion. E. coli strain BL21 is used for expression of zcub5. Cells are transformed by electroporation and grown on minimal glucose plates containing casamino acids and ampicillin. Protein expression is analyzed by gel electrophoresis. Cells are grown in liquid glucose media containing casamino acids and ampicillin. After one hour at 37° C., IPTG is added to a final concentration of 1 mM, and the cells are grown for an additional 2-3 hours at 37° C. Cells are disrupted using glass beads, and extracts are prepared. 
 Example 5 Larger scale cultures of zcub5 transformants are prepared by the method of Pryor and Leiting (ibid.). 100-ml cultures in minimal glucose media containing casamino acids and 100 &mgr;g/ml ampicillin are grown at 37° C. in 500-ml baffled flasks to OD 600 &equals;0.5. Cells are harvested by centrifugation and resuspended in 100 ml of the same media at room temperature. After 15 minutes, IPTG is added to 0.5 mM, and cultures are incubated at room temperature (ca. 22.5° C.) for 16 to 20 hours with shaking at 125 rpm. The culture is harvested by centrifugation, and cell pellets are stored at −70° C. 
 Example 6 For larger-scale protein preparation, 500-ml cultures of E. coli BL21 expressing the zcub5-MBP-His 6 fusion protein are prepared essentially as disclosed in Example 5. Cell pellets are resuspended in 100 ml of Talon binding buffer (20 mM Tris, pH 7.58, 100 mM NaCl, 20 mM NaH 2 PO 4 , 0.4 mM 4-(2-Aminoethyl)-benzenesulfonyl fluoride hydrochloride &lsqb;Pefabloc® SC; Boehringer-Mannheim&rsqb;, 2 35 &mgr;g/ml Leupeptin, 2 &mgr;g/ml Aprotinin). The cells are lysed in a French press at 30,000 psi, and the lysate is centrifuged at 18,000× g for 45 minutes at 4° C. to clarify it. Protein concentration is estimated by gel electrophoresis with a BSA standard. Recombinant zcub5 fusion protein is purified from the lysate by affinity chromatography. Talon resin is equilibrated in binding buffer. One ml of packed resin per 50 mg protein is combined with the clarified supernatant in a tube, and the tube is capped and sealed, then placed on a rocker overnight at 4° C. The resin is then pelleted by centrifugation at 4° C. and washed three times with binding buffer. Protein is eluted with binding buffer containing 0.2M imidazole. The resin and elution buffer are mixed for at least one hour at 4° C., the resin is pelleted, and the supernatant is removed. An aliquot is analyzed by gel electrophoresis, and concentration is estimated. Amylose resin is equilibrated in amylose binding buffer (20 mM Tris-HCl, pH 7.0, 100 mM NaCl, 10 mM EDTA) and combined with the supernatant from the Talon resin at a ratio of 2 mg fusion protein per ml of resin. Binding and washing steps are carried out as disclosed above. Protein is eluted with amylose binding buffer containing 10 mM maltose using as small a volume as possible to minimize the need for subsequent concentration. The eluted protein is analyzed by gel electrophoresis and staining with Coomassie blue using a BSA standard, and by Western blotting using an anti-MBP antibody. 
 Example 7 An expression plasmid containing all or part of a polynucleotide encoding zcub5 is constructed via homologous recombination. A fragment of zcub5 cDNA is isolated by PCR using primers that comprise, from 5′ to 3′ end, 40 bp of flanking sequence from the vector and 17 bp corresponding to the amino and carboxyl termini from the open reading frame of zcub5. The resulting PCR product includes flanking regions at the 5′ and 3′ ends corresponding to the vector sequences flanking the zcub5 insertion point. Ten &mgr;l of the 100 &mgr;l PCR reaction mixture is run on a 0.8% low-melting-temperature agarose (SeaPlaque GTG®; FMC BioProducts, Rockland, ME) gel with 1×TBE buffer for analysis. The remaining 90 &mgr;l of the reaction mixture is precipitated with the addition of 5 &mgr;l 1 M NaCl and 250 &mgr;l of absolute ethanol. The plasmid pZMP6, which has been cut with Smal, is used for recombination with the PCR fragment. Plamid pZMP6 is a mammalian expression vector containing an expression cassette having the cytomegalovirus immediate early promoter, multiple restriction sites for insertion of coding sequences, a stop codon, and a human growth hormone terminator; an E. Coli origin of replication; a mammalian selectable marker expression unit comprising an SV40 promoter, enhancer and origin of replication, a DHER gene, and the SV40 terminator; and URA3 and CEN-ARS sequences required for selection and replication in S. cerevisiae. It was constructed from pZP9 (deposited at the American Type Culture Collection, 10801 University Boulevard, Manassas, Va. 20110-2209, under Accession No. 98668) with the yeast genetic elements taken from pRS316 (deposited at the American Type Culture Collection, 10801 University Boulevard, Manassas, Va. 20110-2209, under Accession No. 77145), an internal ribosome entry site (IRES) element from poliovirus, and the extracellular domain of CD8 truncated at the C-terminal end of the transmembrane domain. One hundred microliters of competent yeast ( S. cerevisiae ) cells are combined with 10 &mgr;l of the DNA preparations from above and transferred to a 0.2-cm electroporation cuvette. The yeast/DNA mixture is electropulsed using power supply (BioRad Laboratories, Hercules, Calif.) settings of 0.75 kV (5 kV/cm), ¢ ohms, 25 &mgr;F. To each cuvette is added 600 &mgr;l of 1.2 M sorbitol, and the yeast is plated in two 300-&mgr;l aliquots onto two URA-D (selective media lacking uracil and containing glucose) plates and incubated at 30° C. After about 48 hours, the Ura &plus; yeast transformants from a single plate are resuspended in 1 ml H 2 O and spun briefly to pellet the yeast cells. The cell pellet is resuspended in 1 ml of lysis buffer (2% Triton X-100, 1% SDS, 100 mM NaCl, 10 mM Tris, pH 8.0, 1 mM EDTA). Five hundred microliters of the lysis mixture is added to an Eppendorf tube containing 300 &mgr;l acid-washed glass beads and 200 11 phenol-chloroform, vortexed for 1 minute intervals two or three times, and spun for 5 minutes in an Eppendorf centrifuge at maximum speed. Three hundred microliters of the aqueous phase is transferred to a fresh tube, and the DNA is precipitated with 600 &mgr;l ethanol (EtOH), followed by centrifugation for 10 minutes at 4° C. The DNA pellet is resuspended in 10 &mgr;l H 2 O. Transformation of electrocompetent E. coli host cells (Electromax DH 10 B™ cells; obtained from Life Technologies, Inc., Gaithersburg, Md.) is done with 0.5-2 ml yeast DNA prep and 40 &mgr;l of cells. The cells are electropulsed at 1.7 kV, 25 &mgr;F, and 400 ohms. Following electroporation, 1 ml SOC (2% Bacto™ Tryptone (Difco, Detroit, Mich.), 0.5% yeast extract (Difco), 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl 2 , 10 mM MgSO 4 , 20 mM glucose) is plated in 250-&mgr;l aliquots on four LB AMP plates (LB broth (Lennox), 1.8% Bacto™ Agar (Difco), 100 mg/L Ampicillin). Individual clones harboring the correct expression construct for zcub5 are identified by restriction digest to verify the presence of the zcub5 insert and to confirm that the various DNA sequences have been joined correctly to one another. The inserts of positive clones are subjected to sequence analysis. Larger scale plasmid DNA is isolated using a commercially available kit (QIAGEN Plasmid Maxi Kit, Qiagen, Valencia, Calif.) according to manufacturer's instructions. The correct construct is designated pZMP6/zcub5. 
 Example 8 CHO DG44 cells (Chasin et al., Som. Cell. Molec. Genet. 12:555-666, 1986) are plated in 10-cm tissue culture dishes and allowed to grow to approximately 50% to 70% confluency overnight at 37° C., 5% CO 2 , in Ham's F12/FBS media (Ham's F12 medium (Life Technologies), 5% fetal bovine serum (Hyclone, Logan, Utah), 1% L-glutamine (JRH Biosciences, Lenexa, Kans.), 1% sodium pyruvate (Life Technologies)). The cells are then transfected with the plasmid zcub5/pZMP6 by liposome-mediated transfection using a 3:1 (w/w) liposome formulation of the polycationic lipid 2,3-dioleyloxy-N-&lsqb;2(sperminecarboxamido)ethyl&rsqb;-N,N-dimethyl-1-propaniminium-trifluoroacetate and the neutral lipid dioleoyl phosphatidylethanolamine in membrane-filetered water (Lipofectamine™ Reagent, Life Technologies), in serum free (SF) media formulation (Ham's F12, 10 mg/ml transferrin, 5 mg/ml insulin, 2 mg/ml fetuin, 1% L-glutamine and 1% sodium pyruvate). pZMP6/zcub5 is diluted into 15-ml tubes to a total final volume of 640 &mgr;l with SF media. 35 &mgr;l of Lipofectamine™ is mixed with 605 &mgr;l of SF medium. The resulting mixture is added to the DNA mixture and allowed to incubate approximately 30 minutes at room temperature. Five ml of SF media is added to the DNA:Lipofectamine™ mixture. The cells are rinsed once with 5 ml of SF media, aspirated, and the DNA:Lipofectamine™ mixture is added. The cells are incubated at 37° C. for five hours, then 6.4 ml of Ham's F12/10% FBS, 1% PSN media is added to each plate. The plates are incubated at 37° C. overnight, and the DNA:Lipofectamine™ mixture is replaced with fresh 5% FBS/Ham's media the next day. On day 3 post-transfection, the cells are split into T-175 flasks in growth medium. On day 7 postransfection, the cells are stained with FITC-anti-CD8 monoclonal antibody (Pharmingen, San Diego, Calif.) followed by anti-FITC-conjugated magnetic beads (Miltenyi Biotec). The CD8-positive cells are separated using commercially available columns (mini-MACS columns; Miltenyi Biotec) according to the manufacturer's directions and put into DMEM/Ham's F12/5% FBS without nucleosides but with 50 nM methotrexate (selection medium). Cells are plated for subcloning at a density of 0.5, 1 and 5 cells per well in 96-well dishes in selection medium and allowed to grow out for approximately two weeks. The wells are checked for evaporation of medium and brought back to 200 &mgr;l per well as necessary during this process. When a large percentage of the colonies in the plate are near confluency, 100 &mgr;l of medium is collected from each well for analysis by dot blot, and the cells are fed with fresh selection medium. The supernatant is applied to a nitrocellulose filter in a dot blot apparatus, and the filter is treated at 100° C. in a vacuum oven to denature the protein. The filter is incubated in 625 mM Tris-glycine, pH 9.1, 5 mM &bgr;-mercaptoethanol, at 65° C., 10 minutes, then in 2.5% non-fat dry milk in Western A Buffer (0.25% gelatin, 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.05% Igepal CA-630) overnight at 4° C. on a rotating shaker. The filter is incubated with the antibody-HRP conjugate in 2.5% non-fat dry milk in Western A buffer for 1 hour at room temperature on a rotating shaker. The filter is then washed three times at room temperature in PBS plus 0.01% Tween 20, 15 minutes per wash. The filter is developed with chemiluminescence reagents (ECL™ direct labelling kit; Amersham Corp., Arlington Heights, Ill.) according to the manufacturer's directions and exposed to film (Hyperfilm ECL, Amersham Corp.) for approximately 5 minutes. Positive clones are trypsinized from the 96-well dish and transferred to 6-well dishes in selection medium for scaleup and analysis by Western blot. 
 Example 9 Full-length zcub5 protein is produced in BHK cells transfected with pZMP6/zcub5 (Example 7). BHK 570 cells (ATCC CRL-10314) are plated in 10-cm tissue culture dishes and allowed to grow to approximately 50 to 70% confluence overnight at 37° C., 5% CO 2 , in DMEM/FBS media (DMEM, Gibco/BRL High Glucose; Life Technologies), 5% fetal bovine serum (Hyclone, Logan, Utah), 1 mM L-glutamine (JRH Biosciences, Lenexa, Kans.), 1 mM sodium pyruvate (Life Technologies). The cells are then transfected with pZMP6/zcub5 by liposome-mediated transfection (using Lipofectanine™; Life Technologies), in serum free (SF) media (DMEM supplemented with 10 mg/mil transferrin, 5 mg/ml insulin, 2 mg/ml fetuin, 1% L-glutamine, and 1% sodium pyruvate). The plasmid is diluted into 15-ml tubes to a total final volume of 640 &mgr;l with SF media. 35 &mgr;l of the lipid mixture is mixed with 605 &mgr;l of SF medium, and the resulting mixture is allowed to incubate approximately 30 minutes at room temperature. Five milliliters of SF media is then added to the DNA:lipid mixture. The cells are rinsed once with 5 ml of SF media, aspirated, and the DNA:lipid mixture is added. The cells are incubated at 37° C. for five hours, then 6.4 ml of DMEM/10% FBS, 1% PSN media is added to each plate. The plates are incubated at 37° C. overnight, and the DNA:lipid mixture is replaced with fresh 5% FBS/DMEM media the next day. On day 5 post-transfection, the cells are split into T-162 flasks in selection medium (DMEM &plus;5% FBS, 1% L-Gln, 1% sodium pyruvate, 1 &mgr;M methotrexate). Approximately 10 days post-transfection, two 150-mm culture dishes of methotrexate-resistant colonies from each transfection are trypsinized, and the cells are pooled and plated into a T-162 flask and transferred to large-scale culture. 
 Example 10 For construction of adenovirus vectors, the protein coding region of human zcub5 is amplified by PCR using primers that add PmeI and AscI restriction sites at the 5′ and 3′ termini respectively. Amplification is performed with a full-length zcub5 cDNA template in a PCR reaction as follows: incubation at 95° C. for 5 minutes; followed by 15 cycles at 95° C. for 1 min., 61° C. for 1 min., and 72° C. for 1.5 min.; followed by 72° C. for 7 min.; followed by a 4° C. soak. The reaction product is loaded onto a 1.2% low-melting-temperature agarose gel in TAE buffer (0.04 M Tris-acetate, 0.001 M EDTA). The zcub5 DNA is excised from the gel and purified using a commercially available kit comprising a silica gel mambrane spin column (QIAquick™ PCR Purification Kit and gel cleanup kit; Qiagen, Inc.) as per kit instructions. The zcub5 DNA is then digested with PmeI and AscI, phenol/chloroform extracted, EtOH precipitated, and rehydrated in 20 ml TE (Tris/EDTA pH 8). The resulting zcub5 fragment is then ligated into the PmeI-AscI sites of the transgenic vector pTG12-8 and transformed into E. coli DH10B™ competent cells by electroporation. Vector pTG 12-8 was derived from p2999B4 (Palniter et al., Mol. Cell Biol. 13:5266-5275, 1993) by insertion of a rat insulin II intron (ca. 200 bp) and polylinker (Fse I/Pme I/Asc I) into the Nru I site. The vector comprises a mouse metallothionein (MT-1) promoter (ca. 750 bp) and human growth hormone (hGH) untranslated region and polyadenylation signal (ca. 650 bp) flanked by 10 kb of MT-1 5′ flanking sequence and 7 kb of MT-1 3′ flanking sequence. The cDNA is inserted between the insulin II and hGH sequences. Clones containing zcub5 are identified by plasmid DNA miniprep followed by digestion with PmeI and AscI. A positive clone is sequenced to insure that there were no deletions or other anomalies in the construct. DNA is prepared using a commercially available kit (Maxi Kit, Qiagen, Inc.), and the zcub5 cDNA is released from the pTG12-8 vector using PmeI and AscI enzymes. The cDNA is isolated on a 1% low melting temperature agarose gel and excised from the gel. The gel slice is melted at 70° C., and the DNA is extracted twice with an equal volume of Tris-buffered phenol, precipitated with EtOH, and resuspended in 10 &mgr;l H 2 O. The zcub5 cDNA is cloned into the EcoRV-AscI sites of a modified pAdTrack-CMV (He, T-C. et al., Proc. Natl. Acad. Sci. USA 95:2509-2514, 1998). This construct contains the green fluorescent protein (GFP) marker gene. The CMV promoter driving GFP expression is replaced with the SV40 promoter, and the SV40 polyadenylation signal is replaced with the human growth hormone polyadenylation signal. In addition, the native polylinker is replaced with FseI, EcoRV, and AscI sites. This modified form of pAdTrack-CMV is named pZyTrack. Ligation is performed using a commercially available DNA ligation and screening kit (Fast-Link™ kit; Epicentre Technologies, Madison, Wis.). Clones containing zcub5 are identified by digestion of mini prep DNA with FseI and AscI. In order to linearize the plasmid, approximately 5 &mgr;g of the resulting pZyTrack zcub5 plasmid is digested with PmeI. Approximately 1 &mgr;g of the linearized plasmid is cotransformed with 200 ng of supercoiled pAdEasy (He et al., ibid.) into E. coli BJ5183 cells (He et al., ibid.). The co-transformation is done using a Bio-Rad Gene Pulser at 2.5 kV, 200 ohms and 25 &mgr;Fa. The entire co-transformation mixture is plated on 4 LB plates containing 25 &mgr;g/ml kanamycin. The smallest colonies are picked and expanded in LB/kanamycin, and recombinant adenovirus DNA is identified by standard DNA miniprep procedures. The recombinant adenovirus miniprep DNA is transformed into E. coli DH10B™ competent cells, and DNA is prepared using a Maxi Kit (Qiagen, Inc.) aaccording to kit instructions. Approximately 5 &mgr;g of recombinant adenoviral DNA is digested with PacI enzyme (New England Biolabs) for 3 hours at 37° C. in a reaction volume of 100 &mgr;l containing 20-30U of PacI. The digested DNA is extracted twice with an equal volume of phenol/chloroform and precipitated with ethanol. The DNA pellet is resuspended in 10 &mgr;l distilled water. A T25 flask of QBI-293A cells (Quantum Biotechnologies, Inc. Montreal, Qc. Canada), inoculated the day before and grown to 60-70% confluence, is transfected with the PacI digested DNA. The PacI-digested DNA is diluted up to a total volume of 50 &mgr;l with sterile HBS (150 mM NaCl, 20 mM HEPES). In a separate tube, 20 &mgr;l of 1 mg/ml N-&lsqb;1-(2,3-Dioleoyloxy)propyl&rsqb;-N,N,N-trimethyl-ammonium salts (DOTAP) (Boehringer Mannheim, Indianapolis, Ind.) is diluted to a total volume of 100 &mgr;l with HBS. The DNA is added to the DOTAP, mixed gently by pipeting up and down, and left at room temperature for 15 minutes. The media is removed from the cells and washed with 5 ml serum-free minimum essential medium (MEM) alpha containing 1 mM sodium pyruvate, 0.1 mM MEM non-essential amino acids, and 25 mM HEPES buffer (reagents obtained from Life Technologies, Gaithersburg, Md.). 5 ml of serum-free MEM is added, and the cells are held at 37° C. The DNA/lipid mixture is added drop-wise to the flask of cells, mixed gently, and incubated at 37° C. for 4 hours. After 4 hours the media containing the DNA/lipid mixture is aspirated off and replaced with 5 ml complete MEM containing 5% fetal bovine serum. The transfected cells are monitored for GFP expression and formation of foci (viral plaques). Seven days after transfection of 293A cells with the recombinant adenoviral DNA, cells expressing GFP start to form foci. The crude viral lysate is collected using a cell scraper to collect the cells. The lysate is transferred to a 50-ml conical tube. To release most of the virus particles from the cells, three freeze/thaw cycles are done in a dry ice/ethanol bath and a 37° waterbath. The crude lysate is amplified (Primary (1°) amplification) to obtain a working stock of zcub5 rAdV lysate. Ten 10 cm plates of nearly confluent (80-90%) 293A cells are set up 20 hours previously, 200 ml of crude rAdV lysate is added to each 10-cm plate, and the cells are monitored for 48 to 72 hours for CPE (cytopathic effect) under the white light microscope and expression of GFP under the fluorescent microscope. When all the cells show CPE, this 1° stock lysate is collected and freeze/thaw cycles are performed as described above. A secondary (2°) amplification of zcub5 rAdV is then performed. Twenty 15-cm tissue culture dishes of 293A cells are prepared so that the cells are 80-90% confluent. All but 20 ml of 5% MEM media is removed, and each dish is inoculated with 300-500 ml of the 1° amplified rAdv lysate. After 48 hours the cells are lysed from virus production, the lysate is collected into 250-ml polypropylene centrifuge bottles, and the rAdV is purified. NP-40 detergent is added to a final concentration of 0.5% to the bottles of crude lysate in order to lyse all cells. Bottles are placed on a rotating platform for 10 minutes agitating as fast as possible without the bottles falling over. The debris is pelleted by centrifugation at 20,000× G for 15 minutes. The supernatant is transferred to 250-ml polycarbonate centrifuge bottles, and 0.5 volume of 20% PEG8000/2.5 M NaCl solution is added. The bottles are shaken overnight on ice. The bottles are centrifuged at 20,000× G for 15 minutes, and the supernatant is discarded into a bleach solution. Using a sterile cell scraper, the white, virus/PEG precipitate from 2 bottles is resuspended in 2.5 ml PBS. The resulting virus solution is placed in 2-ml microcentrifuge tubes and centrifuged at 14,000× G in the microcentrifuge for 10 minutes to remove any additional cell debris. The supernatant from the 2-ml microcentrifuge tubes is transferred into a 15-ml polypropylene snapcap tube and adjusted to a density of 1.34 g/ml with CsCl. The solution is transferred to 3.2-ml, polycarbonate, thick-walled centrifuge tubes and spun at 348,000× G for 3-4 hours at 25° C. The virus forms a white band. Using wide-bore pipette tips, the virus band is collected. A commercially available ion-exchange columns (e.g., PD-10 columns prepacked with Sephadex® G-25M; Pharmacia Biotech, Piscataway, N.J.) is used to desalt the virus preparation. The column is equilibrated with 20 ml of PBS. The virus is loaded and allowed to run into the column. 5 ml of PBS is added to the column, and fractions of 8-10 drops are collected. The optical densities of 1:50 dilutions of each fraction are determined at 260 nm on a spectrophotometer. Peak fractions are pooled, and the optical density (OD) of a 1:25 dilution is determined. OD is converted to virus concentration using the formula: (OD at 260 nm)(25)(1.1×10 12 )&equals;virions/ml. To store the virus, glycerol is added to the purified virus to a final concentration of 15%, mixed gently but effectively, and stored in aliquots at −80° C. A protocol developed by Quantum Biotechnologies, Inc. (Montreal, Canada) is followed to measure recombinant virus infectivity. Briefly, two 96-well tissue culture plates are seeded with 1×10 4 293A cells per well in MEM containing 2% fetal bovine serum for each recombinant virus to be assayed. After 24 hours 10-fold dilutions of each virus from 1×10 −2 to 1×10 −14 are made in MEM containing 2% fetal bovine serum. 100 &mgr;l of each dilution is placed in each of 20 wells. After 5 days at 37° C., wells are read either positive or negative for CPE, and a value for plaque forming units/ml is calculated. From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.